Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres

Human Molecular Genetics

Volumn 19, Issue 11, 2010, Pages 2191-2207

  Trollet, Capucine ^a,b,c,d   Anvar, Seyed Yahya ^e   Venema, Andrea ^e   Hargreaves, Iain P ^f   Foster, Keith ^a   Vignaud, Alban ^b,c,d   Ferry, Arnaud ^b,c,d   Negroni, Elisa ^b,c,d   Hourde, Christophe ^b,c,d   Baraibar, Martin A ^b   't Hoen, Peter A C ^e   Davies, Janet E ^g   Rubinsztein, David C ^g   Heales, Simon J ^f   Mouly, Vincent ^b,c,d   van der Maarel, Silvère M ^e   Butler Browne, Gillian ^b,c,d   Raz, Vered ^e   Dickson, George ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

^c Sorbonne Université   (France)

^d CNRS   (France)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; GENETIC DISORDER; GENETIC REGULATION; MOLECULAR BIOLOGY; MOUSE; MUSCLE ATROPHY; MUSCLE STRENGTH; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PHENOTYPE; PRIORITY JOURNAL; SKELETAL MUSCLE; SOLEUS MUSCLE; TRANSCRIPTOMICS; ANALYSIS OF VARIANCE; ANIMAL; BIOLOGICAL MODEL; COMPLICATION; FAST MUSCLE FIBER; GENE EXPRESSION PROFILING; GENETICS; GLYCOLYSIS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUSCLE CONTRACTION; MUSCULAR ATROPHY; PATHOLOGY; PHYSIOLOGY; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

POLYADENYLIC ACID BINDING PROTEIN;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; GENE EXPRESSION PROFILING; GLYCOLYSIS; IMMUNOHISTOCHEMISTRY; INTRANUCLEAR INCLUSION BODIES; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUSCLE CONTRACTION; MUSCLE FIBERS, FAST-TWITCH; MUSCULAR ATROPHY; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; PHENOTYPE; POLY(A)-BINDING PROTEIN I; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77953586729     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq098     Document Type: Article

References (75)

1. Brais, B., Bouchard, J.P., Xie, Y.G., Rochefort, D.L., Chretien, N., Tome, F.M., Lafreniere, R.G., Rommens, J.M., Uyama, E., Nohira, O. et al. (1998) Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat. Genet., 18, 164-167.
2. Tome, F.M., Chateau, D., Helbling-Leclerc, A. and Fardeau, M. (1997) Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul. Disord., 7 (Suppl. 1), S63-S69.
3. Perie, S., Mamchaoui, K., Mouly, V., Blot, S., Bouazza, B., Thornell, L.E., St Guily, J.L. and Butler-Browne, G. (2006) Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: therapeutic perspectives of autologous myoblast transplantation. Neuromuscul. Disord., 16, 770-781.
4. Kuhn, U., Guendel, M., Knoth, A., Kerwitz, Y., Rudel, S. and Wahle, E. (2009) Poly(A) tail length is controlled by the nuclear poly(A) binding protein regulating the interaction between poly(A) polymerase and the cleavage and polyadenylation specificity factor. J. Biol. Chem., 289, 22803-22814.
5. Wahle, E. (1991) A novel poly(A)-binding protein acts as a specificity factor in the second phase of messenger RNA polyadenylation. Cell, 66, 759-768.
6. Wahle, E. (1995) Poly(A) tail length control is caused by termination of processive synthesis. J. Biol. Chem., 270, 2800-2808.
7. Lemieux, C. and Bachand, F. (2009) Cotranscriptional recruitment of the nuclear poly(A)-binding protein Pab2 to nascent transcripts and association with translating mRNPs. Nucleic Acids Res., 37, 3418-3430.
8. Calado, A., Kutay, U., Kuhn, U., Wahle, E. and Carmo-Fonseca, M. (2000) Deciphering the cellular pathway for transport of poly(A)-binding protein II. RNA, 6, 245-256.
9. Apponi, L.H., Leung, S.W., Williams, K.R., Valentini, S.R., Corbett, A.H. and Pavlath, G.K. (2010) Loss of nuclear poly(A)-binding protein 1 (PABPN1) causes defects in myogenesis and mRNA biogenesis. Hum. Mol. Genet., 19, 1058-1065.
10. Calado, A., Tome, F.M., Brais, B., Rouleau, G.A., Kuhn, U., Wahle, E. and Carmo-Fonseca, M. (2000) Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum. Mol. Genet., 9, 2321-2328.
11. Abu-Baker, A., Messaed, C., Laganiere, J., Gaspar, C., Brais, B. and Rouleau, G.A. (2003) Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum. Mol. Genet., 12, 2609-2623.
12. Tavanez, J.P., Bengoechea, R., Berciano, M.T., Lafarga, M., Carmo-Fonseca, M. and Enguita, F.J. (2009) Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1. PLoS One, 4, e6418.
13. Corbeil-Girard, L.P., Klein, A.F., Sasseville, A.M., Lavoie, H., Dicaire, M.J., Saint-Denis, A., Page, M., Duranceau, A., Codere, F., Bouchard, J.P. et al. (2005) PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol. Dis., 18, 551-567.
14. Fan, X., Messaed, C., Dion, P., Laganiere, J., Brais, B., Karpati, G. and Rouleau, G.A. (2003) HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy. Can. J. Neurol. Sci., 30, 244-251.
15. Tavanez, J.P., Calado, P., Braga, J., Lafarga, M. and Carmo-Fonseca, M. (2005) In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1. RNA, 11, 752-762.
16. Blumen, S.C., Brais, B., Korczyn, A.D., Medinsky, S., Chapman, J., Asherov, A., Nisipeanu, P., Codere, F., Bouchard, J.P., Fardeau, M. et al. (1999) Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann. Neurol., 46, 115-118.
17. Davies, J.E., Sarkar, S. and Rubinsztein, D.C. (2006) Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet., 15, 23-31.
18. Davies, J.E., Wang, L., Garcia-Oroz, L., Cook, L.J., Vacher, C., O'Donovan, D.G. and Rubinsztein, D.C. (2005) Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med., 11, 672-677.
19. Chartier, A., Raz, V., Sterrenburg, E., Verrips, C.T., van der Maarel, S.M. and Simonelig, M. (2009) Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum. Mol. Genet., 18, 1849-1859.
20. Chartier, A., Benoit, B. and Simonelig, M. (2006) A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J., 25, 2253-2262.
21. Klein, A.F., Ebihara, M., Alexander, C., Dicaire, M.J., Sasseville, A.M., Langelier, Y., Rouleau, G.A. and Brais, B. (2008) PABPN1 polyalanine tract deletion and long expansions modify its aggregation pattern and expression. Exp. Cell Res., 314, 1652-1666.
22. Catoire, H., Pasco, M.Y., Abu-Baker, A., Holbert, S., Tourette, C., Brais, B., Rouleau, G.A., Parker, J.A. and Neri, C. (2008) Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum. Mol. Genet., 17, 2108-2117.
23. Messaed, C., Dion, P.A., Abu-Baker, A., Rochefort, D., Laganiere, J., Brais, B. and Rouleau, G.A. (2007) Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy. Neurobiol. Dis., 26, 546-557.
24. Bao, Y.P., Cook, L.J., O'Donovan, D., Uyama, E. and Rubinsztein, D.C. (2002) Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J. Biol. Chem., 277, 12263-12269.
25. Kim, Y.J., Noguchi, S., Hayashi, Y.K., Tsukahara, T., Shimizu, T. and Arahata, K. (2001) The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. Hum. Mol. Genet., 10, 1129-1139.
26. Dion, P., Shanmugam, V., Gaspar, C., Messaed, C., Meijer, I., Toulouse, A., Laganiere, J., Roussel, J., Rochefort, D., Laganiere, S. et al. (2005) Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice. Neurobiol. Dis., 18, 528-536.
27. Hino, H., Araki, K., Uyama, E., Takeya, M., Araki, M., Yoshinobu, K., Miike, K., Kawazoe, Y., Maeda, Y., Uchino, M. et al. (2004) Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet., 13, 181-190.
28. Uyama, E., Hino, H., Araki, K., Takeya, M., Uchino, M. and Yamamura, K. (2005) Animal model of oculopharyngeal muscular dystrophy. Acta Myol., 24, 84-88.
29. Davies, J.E., Sarkar, S. and Rubinsztein, D.C. (2008) Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. Hum. Mol. Genet., 17, 1097-1108.
30. Chatterjee, S. and Price, B. (1991) Regression Analysis by Example. John Wiley and Sons, New York.
31. Pearson, K. (1901) On lines and planes of closest fit to systems of points in space. Philos. Mag., 2, 559-572.
32. Goeman, J.J., van de Geer, S.A., de Kort, F. and van Houwelingen, H.C. (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics, 20, 93-99.
33. Dennis, G. Jr, Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C. and Lempicki, R.A. (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol., 4,3.
34. Huang da, W., Sherman, B.T. and Lempicki, R.A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc., 4, 44-57.
35. Marie-Josee Sasseville, A., Caron, A.W., Bourget, L., Klein, A.F., Dicaire, M.J., Rouleau, G.A., Massie, B., Langelier, Y. and Brais, B. (2006) The dynamism of PABPN1 nuclear inclusions during the cell cycle. Neurobiol. Dis., 23, 621-629.
36. Jelier, R., Schuemie, M.J., Veldhoven, A., Dorssers, L.C., Jenster, G. and Kors, J.A. (2008) Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome Biol., 9, R96.
37. Smyth, G.K. (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol., 3.
38. Sandri, M. (2008) Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda), 23, 160-170.
39. Nury, D., Doucet, C. and Coux, O. (2007) Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting. BMC Biochem., 8 (Suppl. 1), S7.
40. Gilson, H., Schakman, O., Combaret, L., Lause, P., Grobet, L., Attaix, D., Ketelslegers, J.M. and Thissen, J.P. (2007) Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology, 148, 452-460.
41. Vazeille, E., Codran, A., Claustre, A., Averous, J., Listrat, A., Bechet, D., Taillandier, D., Dardevet, D., Attaix, D. and Combaret, L. (2008) The ubiquitin-proteasome and the mitochondria-associated apoptotic pathways are sequentially downregulated during recovery after immobilization-induced muscle atrophy. Am. J. Physiol. Endocrinol. Metab., 295, E1181-E1190.
42. Bodine, S.C., Latres, E., Baumhueter, S., Lai, V.K., Nunez, L., Clarke, B.A., Poueymirou, W.T., Panaro, F.J., Na, E., Dharmarajan, K. et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science, 294, 1704-1708.
43. Bottinelli, R. and Reggiani, C. (2000) Human skeletal muscle fibres: molecular and functional diversity. Prog. Biophys. Mol. Biol., 73, 195-262.
44. Brennan, K.J. and Hardeman, E.C. (1993) Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice. J. Biol. Chem., 268, 719-725.
45. Miniou, P., Tiziano, D., Frugier, T., Roblot, N., Le Meur, M. and Melki, J. (1999) Gene targeting restricted to mouse striated muscle lineage. Nucleic Acids Res., 27, e27.
46. Orengo, J.P., Chambon, P., Metzger, D., Mosier, D.R., Snipes, G.J. and Cooper, T.A. (2008) Expanded CTG repeats within the DMPK 3′-UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc. Natl Acad. Sci. USA, 105, 2646-2651.
47. Wirtschafter, J.D., Ferrington, D.A. and McLoon, L.K. (2004) Continuous remodeling of adult extraocular muscles as an explanation for selective craniofacial vulnerability in oculopharyngeal muscular dystrophy. J. Neuroophthalmol., 24, 62-67.
48. Mouly, V., Aamiri, A., Bigot, A., Cooper, R.N., Di Donna, S., Furling, D., Gidaro, T., Jacquemin, V., Mamchaoui, K., Negroni, E. et al. (2005) The mitotic clock in skeletal muscle regeneration, disease and cell mediated gene therapy. Acta Physiol. Scand., 184, 3-15.
49. Jagoe, R.T., Lecker, S.H., Gomes, M. and Goldberg, A.L. (2002) Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J., 16, 1697-1712.
50. Lecker, S.H., Jagoe, R.T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S.R., Mitch, W.E. and Goldberg, A.L. (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J., 18, 39-51.
51. Sacheck, J.M., Hyatt, J.P., Raffaello, A., Jagoe, R.T., Roy, R.R., Edgerton, V.R., Lecker, S.H. and Goldberg, A.L. (2007) Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J., 21, 140-155.
52. Calura, E., Cagnin, S., Raffaello, A., Laveder, P., Lanfranchi, G. and Romualdi, C. (2008) Meta-analysis of expression signatures of muscle atrophy: gene interaction networks in early and late stages. BMC Genomics, 9, 630.
53. Clarke, B.A., Drujan, D., Willis, M.S., Murphy, L.O., Corpina, R.A., Burova, E., Rakhilin, S.V., Stitt, T.N., Patterson, C., Latres, E. et al. (2007) The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab., 6, 376-385.
54. Cohen, S., Brault, J.J., Gygi, S.P., Glass, D.J., Valenzuela, D.M., Gartner, C., Latres, E. and Goldberg, A.L. (2009) During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol., 185, 1083-1095.
55. Kedar, V., McDonough, H., Arya, R., Li, H.H., Rockman, H.A. and Patterson, C. (2004) Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc. Natl Acad. Sci. USA, 101, 18135-18140.
56. Hirner, S., Krohne, C., Schuster, A., Hoffmann, S., Witt, S., Erber, R., Sticht, C., Gasch, A., Labeit, S. and Labeit, D. (2008) MuRF1-dependent regulation of systemic carbohydrate metabolism as revealed from transgenic mouse studies. J. Mol. Biol., 379, 666-677.
57. Muqit, M.M., Larner, A.J., Sweeney, M.G., Sewry, C., Stinton, V.J., Davis, M.B., Healy, D.G., Payne, S.J., Chotai, K., Wood, N.W. et al. (2008) Multiple mitochondrial DNA deletions in monozygotic twins with OPMD. J. Neurol. Neurosurg. Psychiatry, 79, 68-71.
58. Pauzner, R., Blatt, I., Mouallem, M., Ben-David, E., Farfel, Z. and Sadeh, M. (1991) Mitochondrial abnormalities in oculopharyngeal muscular dystrophy. Muscle Nerve, 14, 947-952.
59. Schroder, J.M., Krabbe, B. and Weis, J. (1995) Oculopharyngeal muscular dystrophy: clinical and morphological follow-up study reveals mitochondrial alterations and unique nuclear inclusions in a severe autosomal recessive type. Neuropathol. Appl. Neurobiol., 21, 68-73.
60. Zhang, Y., Marcillat, O., Giulivi, C., Ernster, L. and Davies, K.J. (1990) The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J. Biol. Chem., 265, 16330-16336.
61. Toriumi, K., Oma, Y., Kino, Y., Futai, E., Sasagawa, N. and Ishiura, S. (2008) Expression of polyalanine stretches induces mitochondrial dysfunction. J. Neurosci. Res., 86, 1529-1537.
62. Toriumi, K., Oma, Y., Mimoto, A., Futai, E., Sasagawa, N., Turk, B. and Ishiura, S. (2009) Polyalanine tracts directly induce the release of cytochrome c, independently of the mitochondrial permeability transition pore, leading to apoptosis. Genes Cells, 14, 751-757.
63. Li, P., Waters, R.E., Redfern, S.I., Zhang, M., Mao, L., Annex, B.H. and Yan, Z. (2007) Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice. Am. J. Pathol., 170, 599-608.
64. Yu, Z., Li, P., Zhang, M., Hannink, M., Stamler, J.S. and Yan, Z. (2008) Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli. PLoS One, 3, e2086.
65. Bruusgaard, J.C., Liestol, K. and Gundersen, K. (2006) Distribution of myonuclei and microtubules in live muscle fibers of young, middle-aged, and old mice. J. Appl. Physiol., 100, 2024-2030.
66. Gundersen, K. and Bruusgaard, J.C. (2008) Nuclear domains during muscle atrophy: nuclei lost or paradigm lost? J. Physiol., 586, 2675-2681.
67. Smyth, G.K. and Speed, T. (2003) Normalization of cDNA microarray data. Methods, 31, 265-273.
68. Vignaud, A., Ramond, F., Hourde, C., Keller, A., Butler-Browne, G. and Ferry, A. (2007) Diabetes provides an unfavorable environment for muscle mass and function after muscle injury in mice. Pathobiology, 74, 291-300.
69. Vignaud, A., Fougerousse, F., Mouisel, E., Guerchet, N., Hourde, C., Bacou, F., Butler-Browne, G.S., Chatonnet, A. and Ferry, A. (2008) Genetic inactivation of acetylcholinesterase causes functional and structural impairment of mouse soleus muscles. Cell Tissue Res., 333, 289-296.
70. Kisselev, A.F. and Goldberg, A.L. (2005) Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol., 398, 364-378.
71. Bulteau, A.L., Lundberg, K.C., Humphries, K.M., Sadek, H.A., Szweda, P.A., Friguet, B. and Szweda, L.I. (2001) Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem., 276, 30057-30063.
72. Ragan, C.I., Wilson, M.Y. and Darley-Usman, V.M. (1988) Subfractionation of mitochondria and isolation of proteins of oxidative phosphorylation. Darley, V.M., Rickwood, D. and Wilson, M.T. (eds), Mitochondria: a Practical Approach. IRL Press, Oxford, pp. 79-113.
73. King, T.E. (1967) Preparation of succinate cytochrome c reductase and cytochrome b-c1 particle and reconstruction of succinate cytochrome c reductase. Methods Enzymol., 10, 446-451.
74. Wharton, D.C. and Tzagoloff, A. (1967) Cytochrome oxidase from beef heart mitochondria. Methods Enzymol., 10, 245-250.
75. Shepherd, J.A. and Garland, P.B. (1969) Citrate synthase activity from rat liver. Methods Enzymol., 13, 11-19.